Clinical Management of Adverse Events Associated with Lorlatinib

Bauer, TM; Felip, E; Solomon, BJ; Thurm, H; Peltz, G; Chioda, MD; Shaw, AT

Bauer, TM (reprint author), Tennessee Oncol PLLC, Sarah Cannon Canc Res Inst, 250 25th Ave N, Nashville, TN 37203 USA.

ONCOLOGIST, 2019; 24 (8): 1103

Abstract

Lorlatinib is a novel, highly potent, brain-penetrant, third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI), which has broad-spectrum potency aga......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索